FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma

Post time 2024-5-6 13:41:01

journal：Clinical Cancer Research

Authors：Michael I. Barbato; Jeannette Nashed; Diana Bradford; Yi Ren; Sachia Khasar; Claudia P. Miller; Banu S. Zolnik; Hong Zhao; Yangbing Li; Youwei Bi; Stacy S. Shord; Anup K. Amatya; Pallavi S. Mishra-Kalyani; Barbara Scepura; Raniya A. Al-Matari; Richard Pazdur; Paul G. Kluetz; Martha Donoghue; Harpreet Singh; Nicole Drezner

Published date：2024-1-17

DOI：10.1158/1078-0432.ccr-23-1503

PDF link：https://aacrjournals.org/clincan ... 714/ccr-23-1503.pdf

Article link：http://dx.doi.org/10.1158/1078-0432.ccr-23-1503

Article Source：American Association for Cancer Research (AACR)。

Remark：

Post time 2024-5-6 13:41:02

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AACR] FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[AACR] FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma Copy